IDYA Latest Press Releases

-- November 3, 2026 --

IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update PRNewswire 6:00 AM

-- October 30, 2026 --

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PRNewswire 6:00 AM

-- October 23, 2026 --

IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas PRNewswire 6:01 AM

-- October 19, 2026 --

IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma PRNewswire 6:00 AM

-- September 28, 2026 --

IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development PRNewswire 6:01 AM

-- September 25, 2026 --

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PRNewswire 6:01 AM

-- September 9, 2026 --

IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma PRNewswire 6:00 AM

-- September 1, 2026 --

IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences PRNewswire 6:00 AM

-- August 31, 2026 --

IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer PRNewswire 6:00 AM

-- August 28, 2026 --

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PRNewswire 6:00 AM

-- August 19, 2026 --

IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer PRNewswire 6:00 AM

-- August 4, 2026 --

IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update PRNewswire 6:00 AM

-- July 31, 2026 --

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PRNewswire 6:00 AM

-- July 27, 2026 --

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers PRNewswire 6:01 AM

-- July 17, 2026 --

IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs PRNewswire 9:00 AM

-- June 26, 2026 --

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PRNewswire 6:01 AM

-- June 17, 2026 --

IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors PRNewswire 6:00 AM

-- June 15, 2026 --

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers PRNewswire 6:01 AM

-- June 10, 2026 --

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares PRNewswire 4:05 PM

-- June 8, 2026 --

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants PRNewswire 10:23 PM

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants PRNewswire 4:01 PM

Market Data Delayed 15 Minutes